Haploidentical stem cell transplantation for myelofibrosis
Haploidentical Hematopoietic Stem Cell Transplantation for the Treatment of Myelofibrosis: A Prospective, Single-center Study
This study is testing a new type of stem cell transplant for people with myelofibrosis to see if it can help those who don’t have a matched donor and improve their chances of recovery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 39 (estimated) |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | ruxolitinib |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06674382 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates a novel haploidentical stem cell transplantation protocol for patients with myelofibrosis, a condition characterized by bone marrow failure and a high risk of leukemia. The study aims to improve outcomes for patients who do not have access to matched donors, as haploidentical donors are more readily available. By evaluating the effectiveness of this new transplantation approach, the trial seeks to address the challenges associated with graft failure and treatment-related mortality. The research is designed to provide a potential cure for myelofibrosis, which currently lacks effective treatment options.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with myelofibrosis who do not have a matched sibling or unrelated donor but have access to a haploidentical donor.
Not a fit: Patients with active infections, very poor performance status, or those with an estimated survival time of less than 30 days may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a curative treatment option for patients with myelofibrosis who lack matched donors.
How similar studies have performed: While haploidentical transplantation has shown promise in treating leukemia, its application in myelofibrosis is less studied, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary disease type: Myelofibrosis (including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or essential thrombocythemia). * No matched sibling donor or unrelated donor, with the availability of a haploidentical donor. * Signed informed consent. Exclusion Criteria: 1. Active infection 2. Very poor performance status (ECOG score \> 2) 3. Estimated survival time \< 30 days 4. Patient or family unable to cooperate 5. Considered unsuitable after discussion
Where this trial is running
Beijing
- Peking University People's Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Sun Yuqian
- Email: sunyuqian83@hotmail.com
- Phone: 861088326666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.